265 related articles for article (PubMed ID: 27591328)
1. Con: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Fernandez Nieto M; Jayne DR
Nephrol Dial Transplant; 2016 Oct; 31(10):1567-71. PubMed ID: 27591328
[TBL] [Abstract][Full Text] [Related]
2. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.
Zhang X; Ji L; Yang L; Tang X; Qin W
Int Urol Nephrol; 2016 May; 48(5):731-43. PubMed ID: 26781720
[TBL] [Abstract][Full Text] [Related]
3. Moderator's view: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Kronbichler A; Neumann I; Mayer G
Nephrol Dial Transplant; 2016 Oct; 31(10):1572-6. PubMed ID: 27591329
[TBL] [Abstract][Full Text] [Related]
4. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Mok CC
Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
[TBL] [Abstract][Full Text] [Related]
5. Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis.
Mejía-Vilet JM; Romero-Díaz J
Expert Rev Clin Immunol; 2021 Sep; 17(9):937-945. PubMed ID: 34392746
[TBL] [Abstract][Full Text] [Related]
6. Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials.
Deng J; Luo L; Zhu L; Xie H; xie H
Turk J Med Sci; 2018 Oct; 48(5):901-910. PubMed ID: 30384552
[TBL] [Abstract][Full Text] [Related]
7. Sequential therapies for proliferative lupus nephritis.
Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
[TBL] [Abstract][Full Text] [Related]
8. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
Jesus D; Rodrigues M; da Silva JAP; Inês L
Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
[TBL] [Abstract][Full Text] [Related]
9. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.
Liu Z; Zhang H; Liu Z; Xing C; Fu P; Ni Z; Chen J; Lin H; Liu F; He Y; He Y; Miao L; Chen N; Li Y; Gu Y; Shi W; Hu W; Liu Z; Bao H; Zeng C; Zhou M
Ann Intern Med; 2015 Jan; 162(1):18-26. PubMed ID: 25383558
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
[TBL] [Abstract][Full Text] [Related]
11. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Fanouriakis A; Kostopoulou M; Cheema K; Anders HJ; Aringer M; Bajema I; Boletis J; Frangou E; Houssiau FA; Hollis J; Karras A; Marchiori F; Marks SD; Moroni G; Mosca M; Parodis I; Praga M; Schneider M; Smolen JS; Tesar V; Trachana M; van Vollenhoven RF; Voskuyl AE; Teng YKO; van Leew B; Bertsias G; Jayne D; Boumpas DT
Ann Rheum Dis; 2020 Jun; 79(6):713-723. PubMed ID: 32220834
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis.
Peleg Y; Bomback AS; Radhakrishnan J
Clin J Am Soc Nephrol; 2020 Jul; 15(7):1066-1072. PubMed ID: 32152065
[TBL] [Abstract][Full Text] [Related]
13. Lupus nephritis: maintenance therapy for lupus nephritis--do we now have a plan?
Lenz O; Waheed AA; Baig A; Pop A; Contreras G
Clin J Am Soc Nephrol; 2013 Jan; 8(1):162-71. PubMed ID: 22917704
[TBL] [Abstract][Full Text] [Related]
14. Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis.
Lenz O; Fornoni A; Contreras G
Drugs; 2005; 65(17):2429-36. PubMed ID: 16296869
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
18. Relative efficacy and safety of calcineurin inhibitor, mycophenolate mofetil, and azathioprine as maintenance therapies for lupus nephritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2024 Feb; 83(Suppl 1):140-147. PubMed ID: 37278824
[TBL] [Abstract][Full Text] [Related]
19. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.
Lee YH; Woo JH; Choi SJ; Ji JD; Song GG
Lupus; 2010 May; 19(6):703-10. PubMed ID: 20064907
[TBL] [Abstract][Full Text] [Related]
20. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
